Glenmark Pharmaceuticals is planning to file close to 20-25 Abbreviated New Drug Applications (ANDAs) each year over the next five years and launch 10-20 products annually. The company’s pipeline of specialty products, to be rolled out over the next 3-4 years, is expected to act as a defence against generic price erosion and increase in competition, and boost profitable growth.
Glenmark’s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
